ABSTRACT
Patients undergoing major surgery experience postoperative inflammation, which may contribute to postoperative morbidity. Endogenous glucocorticoids (GCs) are an essential part of the stress response, but this response varies between individuals, which may in turn affect clinical outcome and specifically postoperative inflammation. Exon 1 of the NR3C1 gene, encoding the GC receptor (GR), contains an established region of differential regulation. DNA methylation patterns in this region have been found to differ between individuals. The present study investigated the methylation status and genotype in the cytosinephosphateguanine (CpG) island in exon 1 of NR3C1 in 24 patients [Median age 65.5 (range 4281) years, 11 male, 13 female] who underwent major abdominal (12 pancreatic, 12 hepatic) surgery and explored its association with postoperative complications. DNA was extracted from peripheral blood leukocytes and underwent targeted bisulfite sequencing of the CpG island. Complications were graded according to the ClavienDindo classification and 14 out of 24 patients had postoperative complications. Multifactorial and partial least square analyses were used to analyse the data. A homogenous demethylated pattern was observed in all patients and no single CpG methylation was associated with postoperative complications. Four SNPs were significantly associated with higher ClavienDindo scores. Genetic variability in the chromosome 5:143,402,505143,405,805 region of exon 1 of the GR gene NR3C1, but not DNA methylation, was associated with more severe postoperative complications in patients having major abdominal surgery. These results indicated that the patients' response to GCs may be of clinical importance for inflammatory conditions.
Subject(s)
Glucocorticoids , Receptors, Glucocorticoid , Adult , Aged , Aged, 80 and over , DNA Methylation , Exons , Female , Humans , Inflammation/genetics , Male , Middle Aged , Postoperative Complications/genetics , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolismABSTRACT
Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4+ T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-α. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , B-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/drug effects , Lymphocyte Activation/drug effects , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/therapy , Aged , Aged, 80 and over , Antigen Presentation/drug effects , Antigen Presentation/immunology , Antigen-Presenting Cells/drug effects , Antigen-Presenting Cells/immunology , B-Lymphocytes/immunology , B7-2 Antigen/immunology , CD4-Positive T-Lymphocytes/immunology , Doxorubicin/administration & dosage , Female , Humans , Immunotherapy/methods , Interleukin-10/immunology , Lymphocyte Activation/immunology , Male , Middle Aged , Tumor Necrosis Factor-alpha/immunology , Urinary Bladder Neoplasms/immunologyABSTRACT
Proper transcriptional control of pro- and anti-inflammatory responses of the immune system is important for a fine-tuned balance between protection and tolerance. Emerging evidence suggests a key role for epigenetic regulation in governing the Th cell differentiation, where effector cytokines direct the overall immune response. In this study, we describe a method to pinpoint the location of isolated human CD4(+) T cells on any T cell effector axis based on specific CpG methylation of cytokine and transcription factor loci. We apply the method on CD4(+) cells obtained from rheumatoid arthritis and multiple sclerosis patients and show that synovial fluid infiltrating CD4(+) T cells are committed toward both Th1 and regulatory T cell phenotype, whereas the Th2 response is suppressed. Furthermore, we show that the IL-17A gene is regulated by promoter methylation and that Th17 commitment is not a common feature in the inflamed joints of rheumatoid arthritis patients. We conclude that the method described in this paper allows for accurate profiling of Th lineage commitment in ex vivo-isolated CD4(+) T cells.